| 前收市價 | 2.3600 |
| 開市 | 2.3600 |
| 買盤 | 0.7500 |
| 賣出價 | 4.4000 |
| 拍板 | 7.50 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 2.3600 - 2.3600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1 |
ZacksCassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
InvestorPlaceStock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant. Moreover, they’re probably
InvestorPlaceExit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas
